Cargando…

Asthma: beyond corticosteroid treatment

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. It is an inflammatory disorder characterized by bronchoconstriction and airway hyperresponsiveness, followed by inflammatory manifestations in the respiratory system. The prevalence of asthma is rising...

Descripción completa

Detalles Bibliográficos
Autores principales: Marandi, Yasser, Farahi, Neda, Hashjin, Goudarz Sadeghi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701968/
https://www.ncbi.nlm.nih.gov/pubmed/23847676
http://dx.doi.org/10.5114/aoms.2013.33179
_version_ 1782275734454140928
author Marandi, Yasser
Farahi, Neda
Hashjin, Goudarz Sadeghi
author_facet Marandi, Yasser
Farahi, Neda
Hashjin, Goudarz Sadeghi
author_sort Marandi, Yasser
collection PubMed
description Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. It is an inflammatory disorder characterized by bronchoconstriction and airway hyperresponsiveness, followed by inflammatory manifestations in the respiratory system. The prevalence of asthma is rising and there is a clinical need to develop more effective treatments. While corticosteroids (glucocorticosteroids) remain the mainstay of asthma therapy, they have limitations because of their potentially severe side-effects and the presence of corticosteroid resistance in some patients. This review discusses current strategies in the treatment of asthma and considers new therapeutic regimens of asthma in the drug development pipeline.
format Online
Article
Text
id pubmed-3701968
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-37019682013-07-11 Asthma: beyond corticosteroid treatment Marandi, Yasser Farahi, Neda Hashjin, Goudarz Sadeghi Arch Med Sci State of the Art Paper Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. It is an inflammatory disorder characterized by bronchoconstriction and airway hyperresponsiveness, followed by inflammatory manifestations in the respiratory system. The prevalence of asthma is rising and there is a clinical need to develop more effective treatments. While corticosteroids (glucocorticosteroids) remain the mainstay of asthma therapy, they have limitations because of their potentially severe side-effects and the presence of corticosteroid resistance in some patients. This review discusses current strategies in the treatment of asthma and considers new therapeutic regimens of asthma in the drug development pipeline. Termedia Publishing House 2013-02-10 2013-06-20 /pmc/articles/PMC3701968/ /pubmed/23847676 http://dx.doi.org/10.5114/aoms.2013.33179 Text en Copyright © 2013 Termedia & Banach http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle State of the Art Paper
Marandi, Yasser
Farahi, Neda
Hashjin, Goudarz Sadeghi
Asthma: beyond corticosteroid treatment
title Asthma: beyond corticosteroid treatment
title_full Asthma: beyond corticosteroid treatment
title_fullStr Asthma: beyond corticosteroid treatment
title_full_unstemmed Asthma: beyond corticosteroid treatment
title_short Asthma: beyond corticosteroid treatment
title_sort asthma: beyond corticosteroid treatment
topic State of the Art Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701968/
https://www.ncbi.nlm.nih.gov/pubmed/23847676
http://dx.doi.org/10.5114/aoms.2013.33179
work_keys_str_mv AT marandiyasser asthmabeyondcorticosteroidtreatment
AT farahineda asthmabeyondcorticosteroidtreatment
AT hashjingoudarzsadeghi asthmabeyondcorticosteroidtreatment